MDS most commonly refers to myelodysplastic syndromes, a group of clonal myeloid malignancies characterized by ineffective hematopoiesis and peripheral blood cytopenias. These syndromes may progress to acute myeloid leukemia in a subset of patients.
Research estimates 300 million people worldwide live with rare diseases, yet only 5% of conditions have approved treatments. Patients face diagnostic delays of 4.7 to 8 years, with emerging AI and machine learning tools showing promise in accelerating diagnosis and drug development.
Cantargia reported full year 2025 financial results with net sales of SEK 316.7 million and cash of SEK 281.8 million. The company secured a SEK 124 million financing package to advance clinical development of nadunolimab, including a phase Ib study combining it with a RAS inhibitor in pancreatic cancer.
The FDA has cleared an IND for Amphista's novel BRD9 degrader AMX-883 for AML, approved Lantheus' new prostate cancer imaging agent Pylarify TruVu, and accepted Biofrontera's sNDA for Ameluz PDT in superficial basal cell carcinoma. These regulatory milestones span hematologic and solid tumor areas, addressing significant unmet medical needs.
The FDA granted Orphan Drug Designation to Cullinan Therapeutics’ CLN-049 for relapsed/refractory AML. CLN-049 is in Phase 1 studies and had already received Fast Track designation.
Faron Pharmaceuticals announces acceptance of bexmarilimab Phase I/II data for poster presentation at BSH 2026, while launching a new Phase II BEAM-X study evaluating the drug in AML patients post-stem cell transplantation.
Higher consumption of ultraprocessed food after cancer diagnosis is associated with increased rates of all-cause and cancer mortality, regardless of overall diet quality, according to a study of 802 cancer survivors.
Faron Pharmaceuticals announces Phase II BEAM-X trial evaluating bexmarilimab plus azacitidine in MRD-positive AML patients after stem cell transplantation. The Nordic AML Group-led trial will enroll 24 patients with first results expected 12-15 months after enrollment begins in Q3 2026.
The FDA has approved Filkri (filgrastim-laha), a biosimilar to Neupogen, for cancer patients at risk of infection due to chemotherapy and other indications. The approval marks Accord BioPharma's sixth biosimilar product.
The FDA approved 46 novel drugs in 2025, down from 50 in 2024. Small molecules accounted for 31 approvals (67%), with oncology leading at nine approvals. Large molecules contributed 15 approvals (33%), spanning ADCs, bispecifics, and subcutaneous delivery innovations.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07575412 |
SHR2554/AZA + Overlapped Modified BUCY for High-risk/Relapsed Leukemia/MDS |
NOT_YET_RECRUITING | PHASE2 |
| NCT07562568 |
SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS |
NOT_YET_RECRUITING | PHASE2 |
| NCT07493538 |
MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases |
RECRUITING | PHASE2 |
| NCT07387354 |
Pacritinib With Aza for Upfront Myelodysplastic Syndrome |
NOT_YET_RECRUITING | PHASE1/PHASE2 |
| NCT07347171 |
A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies |
RECRUITING | PHASE1 |
| NCT07328191 |
Quality of Life-Guided Transfusion in Refractory MDS or AML |
RECRUITING | NA |
| NCT07318662 |
Efficacy and Safety of HMAs Combined With Venetoclax Versus HMAs Alone in ND Int-and H-risk MDS or CMML |
ACTIVE_NOT_RECRUITING | |
| NCT07205523 |
High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT) |
RECRUITING | |
| NCT07131085 |
QH101 Cell Therapy Relapsed/Refractory(R/R) Acute Myeloid Leukemia(AML) and Myelodysplastic Syndromes(MDS) |
NOT_YET_RECRUITING | PHASE1 |
| NCT07085156 |
Reduced Intensity Conditioning for MDS |
NOT_YET_RECRUITING | PHASE2 |
